Clinical trial · no report yet · Phase 2
Neo-KAN
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
- NCT05472623 ↗
- Withdrawn
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Trial of Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)
- Phase
- Phase 2
- Status
- Withdrawn
- Conditions
- Resectable Non-Small Cell Lung Cancer
- Interventions
- Adagrasib; Adagrasib/Nivolumab
- Arms
- Arm A · Active comparator
- Arm B · Active comparator
- Enrollment
- 0
- Primary outcomes
- Pathologic complete response (pCR) rate
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins with Mirati Therapeutics Inc., Bristol-Myers Squibb
- Start
- Mar 21, 2023
- Primary completion
- Jun 1, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05472623 · updated Sep 15, 2025
Publications
linked from the registry- Luo J, Florez N, Donnelly A, Lou Y, Lu K, Ma PC, Spira AI, Ryan D, Husain H. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precis Oncol. 2024 Apr;8:e2300644. doi: 10.1200/PO.23.00644. PubMed 38579193